Browse by People

Collapse authors list.
Cahn, Avivit, Wiviott, Stephen D, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Lawrence A, Bhatt, Deepak L et al (show 8 more authors) , McGuire, Darren K, Litwak, Leon, Kooy, Adriaan, Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2021) Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM, 23 (1). pp. 29-38.

Collapse authors list.
Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404 et al (show 8 more authors) , Cahn, Avivit, Gause-Nilsson, Ingrid AM, Johanson, Per, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Raz, Itamar and Sabatine, Marc S (2020) Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142 (8). pp. 734-747.

Collapse authors list.
Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D, Schechter, Meir, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A, Zelniker, Thomas A, Langkilde, Anna Maria et al (show 11 more authors) , Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Wilding, John PH ORCID: 0000-0003-2839-8404, McGuire, Darren K, Bhatt, Deepak L, Leiter, Lawrence A, Cahn, Avivit, Dwyer, Jamie P, Heerspink, Hiddo JL and Sabatine, Marc S (2022) Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. DIABETES CARE, 45 (10). pp. 2350-2359.

Collapse authors list.
Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P et al (show 11 more authors) , Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Kato, Eri T, Gause-Nilson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). pp. 606-617.

Collapse authors list.
Schechter, Meir, Wiviott, Stephen, Raz, Itamar, Goodrich, Erica L, Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina A, Zelniker, Thomas A, Fredriksson, Martin, Johansson, Peter A et al (show 9 more authors) , Leiter, Lawrence A, Bhatt, Deepak L, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid AM, Cahn, Avivit, Langkilde, Anna Maria, Sabatine, Marc S and Mosenzon, Ofri (2023) Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. LANCET DIABETES & ENDOCRINOLOGY, 11 (4). pp. 233-241.

Collapse authors list.
Cahn, Avivit, Mosenzon, Ofri, Wiviott, Stephen D, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K et al (show 7 more authors) , Wilding, John PH ORCID: 0000-0003-2839-8404, Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Langkilde, Anna Maria, Sabatine, Marc S and Raz, Itamar (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. DIABETES CARE, 43 (2). pp. 468-475.

Collapse authors list.
Cahn, Avivit, Raz, Itamar, Bonaca, Marc, Mosenzon, Ofri, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Bhatt, Deepak L, McGuire, Darren K et al (show 9 more authors) , Gause-Nilsson, Ingrid AM, Fredriksson, Martin, Johansson, Peter A, Jermendy, Gyorgy, Hadjadj, Samy, Langkilde, Anna Maria, Sabatine, Marc S, Wiviott, Stephen D and Leiter, Lawrence A (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22 (8). pp. 1357-1368.